Last Updated: May 3, 2026

Litigation Details for Viasat, Inc. v. Intellectual Ventures I LLC (D. Del. 2025)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Viasat, Inc. v. Intellectual Ventures I LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary & Patent Analysis: Viasat, Inc. v. Intellectual Ventures I LLC (D. Del. 1:25-cv-00056)

Last updated: April 27, 2026

What is the case status and what is being disputed?

Viasat, Inc. v. Intellectual Ventures I LLC is filed in the U.S. District Court for the District of Delaware under docket number 1:25-cv-00056. The case title indicates that Viasat is the plaintiff and Intellectual Ventures I LLC is the defendant.

No further case-specific details (asserted patents, claims, technology, infringement theories, claim construction, procedural posture, or final outcomes) are available in the provided information.

Which patents and claims are at issue?

The patents-in-suit and the specific asserted claim numbers are not provided in the supplied materials. Without those identifiers, a claim-by-claim infringement and validity analysis cannot be constructed.

What do the parties’ litigation positions likely hinge on?

Without the complaint, amended pleadings, or docket entries showing the asserted claims and defenses, the litigation’s hinge points (infringement elements, anticipation/obviousness theories, invalidity grounds, and any written description or indefiniteness arguments) cannot be determined from the provided information.

What is the likely technical and product scope implicated by the parties’ names?

The docket number and party identities alone do not define the accused technology. Viasat’s business spans satellite communications and related services; Intellectual Ventures I LLC typically builds portfolios around communications and data networking. But the record needed to map a specific portfolio to specific Viasat systems is not present in the provided information.

What procedural milestones matter for investment and R&D decisions?

In the absence of docket details, the milestones that normally drive risk (motions to dismiss, transfer/venue outcomes, Markman scheduling, early summary judgment, stay motions for PTAB proceedings, or discovery orders) cannot be tied to dates or outcomes in this matter.

Claim strategy: what can be analyzed from the available record?

No claim construction, asserted claim text, or claim charts are provided. As a result, it is not possible to produce:

  • a limitation-by-limitation infringement map,
  • a non-infringement theory tied to a specific claim element,
  • a patentability analysis grounded in specific prior art,
  • an estoppel analysis tied to PTAB outcomes, or
  • an enforceability/indefiniteness evaluation tied to the asserted claims.

Damages exposure: what is knowable now?

No asserted damages framework, royalty base, comparable license evidence, or time window is provided. Without the asserted patents and claims, damages exposure cannot be quantified.

Bottom line: litigation risk read-through

The information provided identifies the case caption and docket number only. No material facts are present to support an actionable infringement/validity or procedural risk assessment.

Key Takeaways

  • The case is Viasat, Inc. v. Intellectual Ventures I LLC, D. Del., 1:25-cv-00056.
  • The provided record does not include asserted patents, asserted claims, technology details, procedural posture, or filed motions/outcomes.
  • A patent-level litigation analysis (infringement, validity, and damages) cannot be produced from the available information.

FAQs

1) What court and docket number is this?

U.S. District Court for the District of Delaware, docket 1:25-cv-00056.

2) Who are the parties?

Viasat, Inc. and Intellectual Ventures I LLC.

3) What patents are asserted?

Not provided in the supplied information.

4) What stage is the case in?

Not provided in the supplied information.

5) Can damages or invalidity be analyzed now?

Not from the information provided, because asserted patents, claims, and docket events are missing.


References

[1] Viasat, Inc. v. Intellectual Ventures I LLC, No. 1:25-cv-00056 (D. Del. 2025).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.